Oncoinvent secures new patent expanding protection for Radspherin®
First patent from a new patent family granted in China, strengthening the long‑term intellectual property protection for the Company’s lead product candidate
Oslo, Norway, 19 March 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin®, the Company’s lead product candidate, marking the first approval worldwide within this patent family.
